| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| equivalentClass
| |
| Has_Free_Acid_Or_Base_Form
| |
| Has_Target
| |
| Concept_In_Subset
| |
| Semantic_Type
| - Organic Chemical
- Pharmacologic Substance
|
| Preferred_Name
| |
| NSC_Code
| |
| UMLS_CUI
| |
| CAS_Registry
| |
| Accepted_Therapeutic_Use_For
| - Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia, gastrointestinal stromal tumor, hypereosinophillic syndrome, dermatofibrosarcoma protuberans, mutated-PDGFR myelodysplastic/myeloproliferative diseases.
|
| In_Clinical_Trial_For
| - Acute lymphoblastic leukemia; breast cancer; chronic myelogenous leukemia; colorectal cancer; gastrointestinal neoplasms; glioma; melanoma; Merkel cell carcinoma
- Metastatic dermatofibrosarcoma protuberans; myelofibrosis; ovarian epithelial; fallopian tube; or primary peritoneal cancer; prostate cancer; small cell lung cancer; unspecified solid tumors; uterine carcinoma
|
| FDA_UNII_Code
| |
| Contributing_Source
| |
| ALT_DEFINITION
| - A drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Imatinib mesylate blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Chemical_Formula
| |
| Legacy_Concept_Name
| |
| CHEBI_ID
| |
| FULL_SYN
| - imatinib mesylatePTNCI-GLOSSCDR0000044893
- Imatinib MesylatePTDCP50363
- 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide MonomethanesulfonateSNNCI
- STI 571SYDTPNSC0716051
- STI571PTNCI-GLOSSCDR0000043975
- GleevecSYDTPNSC0716051
- Imatinib MesylatePTNCI
- STI571CNNCI
- IMATINIB MESYLATEPTFDA8A1O1M485B
- GlivecFBNCI
- GleevecPTNCI-GLOSSCDR0000258252
- STI-571CNNCI
- GleevecBRNCI
- CGP 57148CNNCI
- CGP57148BCNNCI
|
| DEFINITION
| - The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).NCI
|
| code
| |
| sameAs
| |
| http://linked.open...y/mesh/hasConcept
| |
| is someValuesFrom
of | |
| is Has_Salt_Form
of | |
| is sameAs
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)